List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8041323/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. Journal of Hepatology, 2017, 66, 1037-1046.	3.7	738
2	HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. Journal of Hepatology, 2018, 68, 25-32.	3.7	393
3	Trends in Burden of Cirrhosis and Hepatocellular Carcinoma by Underlying Liver Disease in US Veterans, 2001–2013. Gastroenterology, 2015, 149, 1471-1482.e5.	1.3	368
4	The Role of Cholesterol in the Pathogenesis of NASH. Trends in Endocrinology and Metabolism, 2016, 27, 84-95.	7.1	347
5	Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10â€ ⁻ 131 US Veterans With SARS-CoV-2 Infection. JAMA Network Open, 2020, 3, e2022310.	5.9	305
6	The Prevalence and Predictors of Elevated Serum Aminotransferase Activity in the United States in 1999-2002. American Journal of Gastroenterology, 2006, 101, 76-82.	0.4	286
7	Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. Clinical Gastroenterology and Hepatology, 2005, 3, 67-74.	4.4	283
8	Hepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic Steatohepatitis. Gastroenterology, 2011, 141, 1393-1403.e5.	1.3	279
9	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology, 2019, 157, 1264-1278.e4.	1.3	252
10	Liver Transplantation for Hepatocellular Carcinoma: Impact of the MELD Allocation System and Predictors of Survival. Gastroenterology, 2008, 134, 1342-1351.	1.3	240
11	Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2007, 5, 938-945.e4.	4.4	234
12	Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology, 2013, 57, 81-92.	7.3	219
13	Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology, 2006, 43, 1145-1151.	7.3	207
14	Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice. Journal of Lipid Research, 2011, 52, 1626-1635.	4.2	196
15	Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology, 2016, 151, 457-471.e5.	1.3	195
16	The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency and iron deficiency anemia. Gastroenterology, 2004, 126, 1293-1301.	1.3	182
17	Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis. Journal of Lipid Research, 2013, 54, 1326-1334.	4.2	180
18	The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology, 2013, 57, 249-257.	7.3	171

#	Article	IF	CITATIONS
19	Epidemiology and risk-stratification of NAFLD-associated HCC. Journal of Hepatology, 2021, 75, 1476-1484.	3.7	160
20	Terlipressin in acute oesophageal variceal haemorrhage. Alimentary Pharmacology and Therapeutics, 2003, 17, 53-64.	3.7	153
21	Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. Gastroenterology, 2016, 150, 441-453.e6.	1.3	150
22	What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?. Gastroenterology, 2019, 156, 446-460.e2.	1.3	149
23	Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transplantation, 2013, 19, 634-645.	2.4	143
24	Hepatitis B Virus in the United States: Infection, Exposure, and Immunity Rates in a Nationally Representative Survey. Annals of Internal Medicine, 2011, 154, 319.	3.9	142
25	ls Obesity Associated With Anemia of Chronic Disease? A Populationâ€based Study. Obesity, 2008, 16, 2356-2361.	3.0	141
26	Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population. Hepatology, 2009, 50, 175-184.	7.3	138
27	Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. Nature Communications, 2018, 9, 4490.	12.8	135
28	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Gastroenterology, 2019, 157, 1253-1263.e2.	1.3	131
29	Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Diabetes Care, 2017, 40, 1173-1180.	8.6	130
30	Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transplantation, 2012, 18, 29-37.	2.4	124
31	Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. Journal of Hepatology, 2019, 71, 523-533.	3.7	124
32	Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 32-39.	3.7	121
33	Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. Journal of Hepatology, 2018, 69, 1088-1098.	3.7	119
34	Development and validation of a model predicting graft survival after liver transplantation. Liver Transplantation, 2006, 12, 1594-1606.	2.4	117
35	Iron deficiency and gastrointestinal malignancy: a population-based cohort study. American Journal of Medicine, 2002, 113, 276-280.	1.5	115
36	Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. Journal of Lipid Research, 2017, 58, 1067-1079.	4.2	111

#	Article	IF	CITATIONS
37	ls obesity a risk factor for cirrhosis-related death or hospitalization? a population-based cohort study. Gastroenterology, 2003, 125, 1053-1059.	1.3	107
38	Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. Journal of Hepatology, 2013, 59, 144-152.	3.7	105
39	Association between serum uric acid level and chronic liver disease in the United States. Hepatology, 2010, 52, 578-589.	7.3	102
40	Improved Surveillance for Hepatocellular Carcinoma With a Primary Care–Oriented Clinical Reminder. Clinical Gastroenterology and Hepatology, 2015, 13, 172-179.	4.4	92
41	HCC surveillance after SVR in patients with F3/F4 fibrosis. Journal of Hepatology, 2021, 74, 458-465.	3.7	86
42	Risk Prediction Models for Postâ€Operative Mortality in Patients With Cirrhosis. Hepatology, 2021, 73, 204-218.	7.3	83
43	No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 155, 1128-1139.e6.	1.3	80
44	Role of Cholesterolâ€Associated Steatohepatitis in the Development of NASH. Hepatology Communications, 2022, 6, 12-35.	4.3	80
45	Portal Vein Thrombosis Is Not Associated With Increased Mortality Among Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2015, 13, 585-593.	4.4	79
46	Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. PLoS ONE, 2018, 13, e0204412.	2.5	77
47	Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. JAMA Network Open, 2020, 3, e2015626.	5.9	75
48	The selective peroxisome proliferator–activated receptorâ€delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatology Communications, 2017, 1, 663-674.	4.3	69
49	Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology, 2005, 128, 627-635.	1.3	68
50	The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Hepatology, 2017, 65, 426-438.	7.3	68
51	Incidence of and Risk Factors for Hepatic Encephalopathy in a Populationâ€Based Cohort of Americans With Cirrhosis. Hepatology Communications, 2019, 3, 1510-1519.	4.3	66
52	Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality. Hepatology, 2021, 74, 322-335.	7.3	66
53	TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival. Clinical Science, 2017, 131, 2145-2159.	4.3	64
54	Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH. Journal of Lipid Research, 2015, 56, 277-285.	4.2	63

#	Article	IF	CITATIONS
55	Survival of Liver Transplant Recipients With Hemochromatosis in the United States. Gastroenterology, 2007, 133, 489-495.	1.3	62
56	Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes. Journal of Diabetes and Its Complications, 2007, 21, 363-370.	2.3	59
57	Comparison of Liver Transplant–Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States. Gastroenterology, 2015, 149, 669-680.	1.3	59
58	Machine learning models to predict disease progression among veterans with hepatitis C virus. PLoS ONE, 2019, 14, e0208141.	2.5	59
59	Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug and Alcohol Dependence, 2016, 169, 101-109.	3.2	58
60	Prospective evaluation of a clinical guideline for the diagnosis and management of iron deficiency anemia. American Journal of Medicine, 2002, 113, 281-287.	1.5	57
61	Prevalence and Treatment of Chronic Hepatitis C Virus Infection in the US Department of Veterans Affairs. Epidemiologic Reviews, 2015, 37, 131-143.	3.5	53
62	Is Helicobacter pylori seropositivity related to body mass index in the United States?. Alimentary Pharmacology and Therapeutics, 2005, 21, 765-772.	3.7	52
63	Impact of exposure to patients with COVID-19 on residents and fellows: an international survey of 1420 trainees. Postgraduate Medical Journal, 2021, 97, 706-715.	1.8	52
64	Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology, 2003, 37, 795-801.	7.3	51
65	Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. European Journal of Gastroenterology and Hepatology, 2017, 29, 686-693.	1.6	50
66	Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis. Hepatology Communications, 2019, 3, 776-791.	4.3	50
67	Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?. American Journal of Transplantation, 2012, 12, 706-717.	4.7	47
68	Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents. Alimentary Pharmacology and Therapeutics, 2017, 45, 1201-1212.	3.7	47
69	Similar Effectiveness of Boceprevir and Telaprevir Treatment Regimens for Hepatitis C Virus Infection on the Basis of a Nationwide Study of Veterans. Clinical Gastroenterology and Hepatology, 2014, 12, 1371-1380.	4.4	46
70	Serum bilirubin and colorectal cancer risk: a population-based cohort study. Alimentary Pharmacology and Therapeutics, 2006, 23, 1637-1642.	3.7	41
71	Predictors of Early Treatment Discontinuation Among Patients With Genotype 1 Hepatitis C and Implications for Viral Eradication. Clinical Gastroenterology and Hepatology, 2010, 8, 972-978.	4.4	41
72	COVID-19 Vaccination Effectiveness Against Infection or Death in a National U.S. Health Care System. Annals of Internal Medicine, 2022, 175, 352-361.	3.9	41

#	Article	IF	CITATIONS
73	Association Between Transjugular Intrahepatic Portosystemic Shunt and Survival in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2016, 14, 118-123.	4.4	40
74	Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice. Obesity, 2017, 25, 155-165.	3.0	40
75	Survival after orthotopic liver transplantation: The impact of antibody against hepatitis B core antigen in the donor. Liver Transplantation, 2009, 15, 1343-1350.	2.4	35
76	Risk Factors for Testing Positive for Severe Acute Respiratory Syndrome Coronavirus 2 in a National United States Healthcare System. Clinical Infectious Diseases, 2021, 73, e3085-e3094.	5.8	35
77	Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. PLoS ONE, 2017, 12, e0189965.	2.5	35
78	Use of Antibiotics Among Patients With Cirrhosis and Upper Gastrointestinal Bleeding Is Associated With Reduced Mortality. Clinical Gastroenterology and Hepatology, 2016, 14, 1629-1637.e1.	4.4	34
79	Mouse models of nonâ€alcoholic steatohepatitis: A reflection on recent literature. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1312-1320.	2.8	34
80	Incidence and Risk Factors of Postoperative Mortality and Morbidity After Elective Versus Emergent Abdominal Surgery in a National Sample of 8193 Patients With Cirrhosis. Annals of Surgery, 2021, 274, e345-e354.	4.2	33
81	Development of COVIDVax Model to Estimate the Risk of SARS-CoV-2–Related Death Among 7.6 Million US Veterans for Use in Vaccination Prioritization. JAMA Network Open, 2021, 4, e214347.	5.9	33
82	Cholelithiasis, Cholecystectomy, and Liver Disease. American Journal of Gastroenterology, 2010, 105, 1364-1373.	0.4	30
83	Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system. EClinicalMedicine, 2022, 45, 101326.	7.1	29
84	Exercise retards hepatocarcinogenesis in obese mice independentlyÂof weight control. Journal of Hepatology, 2020, 73, 140-148.	3.7	28
85	BMI and Outcomes of SARSâ€CoVâ€2 Among US Veterans. Obesity, 2021, 29, 900-908.	3.0	28
86	Pcsk9 Deletion Promotes Murine Nonalcoholic Steatohepatitis and Hepatic Carcinogenesis: Role of Cholesterol. Hepatology Communications, 2022, 6, 780-794.	4.3	28
87	Effects of menopause and hormone replacement therapy on the associations of hyperuricemia with mortality. Atherosclerosis, 2013, 226, 220-227.	0.8	27
88	Relationship between serum circulating insulinâ€like growth factorâ€1 and liver fat in the <scp>U</scp> nited <scp>S</scp> tates. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 589-596.	2.8	26
89	Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach. Metabolites, 2020, 10, 168.	2.9	26
90	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology, 2022, 75, 1289-1299.	7.3	26

#	Article	IF	CITATIONS
91	Relationship Between Transferrin-Iron Saturation, Alcohol Consumption, and the Incidence of Cirrhosis and Liver Cancer. Clinical Gastroenterology and Hepatology, 2007, 5, 624-629.	4.4	25
92	Associations Between Alcohol Use and Liverâ€Related Outcomes in a Large National Cohort of Patients With Cirrhosis. Hepatology Communications, 2021, 5, 2080-2095.	4.3	25
93	No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut, 2021, 70, gutjnl-2019-319867.	12.1	24
94	Genetic ablation of <i>Cyp8b1</i> preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E418-E432.	3.5	22
95	Hepatitis C eradication with directâ€acting antiâ€virals reduces the risk of variceal bleeding. Alimentary Pharmacology and Therapeutics, 2020, 51, 364-373.	3.7	22
96	PM2.5 air pollution exposure and nonalcoholic fatty liver disease in the Nationwide Inpatient Sample. Environmental Research, 2022, 213, 113611.	7.5	22
97	Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. Drug and Alcohol Dependence, 2018, 188, 79-85.	3.2	21
98	Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C. Digestive Diseases and Sciences, 2021, 66, 2394-2406.	2.3	21
99	Disparities in Waitlist and Posttransplantation Outcomes in Liver Transplant Registrants and Recipients Aged 18 to 24 Years. Transplantation, 2017, 101, 1616-1627.	1.0	20
100	Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. Clinical Gastroenterology and Hepatology, 2020, 18, 1197-1206.e7.	4.4	20
101	Trends Over Time in the Risk of Adverse Outcomes Among Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clinical Infectious Diseases, 2022, 74, 416-426.	5.8	20
102	Dietary Cholesterol Intake Is Associated With Progression of Liver Disease in Patients With Chronic Hepatitis C: Analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Clinical Gastroenterology and Hepatology, 2013, 11, 1661-1666.e3.	4.4	19
103	Implications of <scp>HCV RNA</scp> level at week 4 of direct antiviral treatments for hepatitis C. Journal of Viral Hepatitis, 2017, 24, 966-975.	2.0	18
104	Transplantâ€felated survival benefit should influence prioritization for liver transplantation especially in patients with hepatocellular carcinoma. Liver Transplantation, 2017, 23, 652-662.	2.4	18
105	Hepatitis C–Related Hepatocellular Carcinoma Incidence in the Veterans Health Administration After Introduction of Direct-Acting Antivirals. JAMA - Journal of the American Medical Association, 2020, 324, 1003.	7.4	17
106	Chronic hepatitis B infection: A global disease requiring global strategies. Hepatology, 2013, 58, 839-843.	7.3	16
107	Hepatocellular Carcinoma Risk After Directâ€Acting Antiviral Therapy. Clinical Liver Disease, 2019, 13, 6-12.	2.1	16
108	Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2020, 18, 974-983.	4.4	16

#	Article	IF	CITATIONS
109	Changes in the associations of race and rurality with SARS-CoV-2 infection, mortality, and case fatality in the United States from February 2020 to March 2021: A population-based cohort study. PLoS Medicine, 2021, 18, e1003807.	8.4	16
110	Fast macromolecular proton fraction mapping of the human liver <i>in vivo</i> for quantitative assessment of hepatic fibrosis. NMR in Biomedicine, 2015, 28, 1716-1725.	2.8	15
111	Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clinical Gastroenterology and Hepatology, 2022, 20, 183-193.	4.4	15
112	Rates and predictors of response to antiâ€viral treatment for hepatitis C virus in <scp>HIV</scp> / <scp>HCV</scp> coâ€infection in a nationwide study of 619 patients. Alimentary Pharmacology and Therapeutics, 2013, 38, 1373-1384.	3.7	14
113	The Impact of Direct-acting Antiviral Therapy for Hepatitis C on Hepatocellular Carcinoma Risk. Current Hepatology Reports, 2018, 17, 377-384.	0.9	14
114	Factors associated with early receipt of COVID-19 vaccination and adherence to second dose in the Veterans Affairs healthcare system. PLoS ONE, 2021, 16, e0259696.	2.5	14
115	The COVID-19 Pandemic Highlights Opportunities to Improve Hepatocellular Carcinoma Screening and Diagnosis in a National Health System. American Journal of Gastroenterology, 2022, 117, 678-684.	0.4	14
116	Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. Journal of Hepatology, 2021, 74, 850-859.	3.7	13
117	SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials, 2021, 104, 106367.	1.8	13
118	Fibroscan liver stiffness after antiâ€viral treatment for hepatitis C is independently associated with adverse outcomes. Alimentary Pharmacology and Therapeutics, 2020, 52, 1717-1727.	3.7	13
119	Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: AASystematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2023, 21, 1723-1738.e5.	4.4	12
120	Can Computerized Brain Training Games be Used to Identify Early Cognitive Impairment in Cirrhosis?. American Journal of Gastroenterology, 2014, 109, 316-323.	0.4	11
121	Characteristics and outcomes of transjugular intrahepatic portosystemic shunt recipients in the VA Healthcare System. European Journal of Gastroenterology and Hepatology, 2016, 28, 667-675.	1.6	11
122	Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Directâ€Acting Antivirals. Hepatology Communications, 2019, 3, 1124-1136.	4.3	11
123	Alcohol Use and Longâ€Term Outcomes Among U.S. Veterans Who Received Directâ€Acting Antivirals for Hepatitis C Treatment. Hepatology Communications, 2020, 4, 314-324.	4.3	11
124	Associations between lipodystrophy or antiretroviral medications and cirrhosis in patients with HIV infection or HIV/HCV coinfection. European Journal of Gastroenterology and Hepatology, 2015, 27, 577-584.	1.6	10
125	Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. American Journal of Gastroenterology, 2021, 116, 411-415.	0.4	9
126	A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma–Initial, Maximum, Last Classification. Liver Transplantation, 2019, 25, 559-570.	2.4	7

#	Article	IF	CITATIONS
127	No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. European Journal of Gastroenterology and Hepatology, 2019, 31, 47-52.	1.6	7
128	Risk factors for adverse outcomes in emergency versus nonemergency open umbilical hernia repair and opportunities for elective repair in a national cohort of patients with cirrhosis. Surgery, 2022, 172, 184-192.	1.9	7
129	Hepatocellular Carcinoma Risk Declines but Remains High Enough for Screening in the First 7 Years After Hepatitis C Virus Cure With Direct-Acting Antivirals in Patients With Cirrhosis or High Fibrosis-4 Score. Gastroenterology, 2022, 163, 1104-1106.e3.	1.3	7
130	Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. European Journal of Gastroenterology and Hepatology, 2015, 27, 123-129.	1.6	6
131	Prevalence and Management of Chronic Hepatitis C Virus Infection in Women. Medical Clinics of North America, 2015, 99, 575-586.	2.5	6
132	For Whom is Hepatocellular Carcinoma Surveillance After Sustained Virologic Response Cost-Effective?. Clinical Gastroenterology and Hepatology, 2019, 17, 1732-1735.	4.4	5
133	Prevalence of Hepatitis B Virus Exposure in the Veterans Health Administration and Association With Military-Related Risk Factors. Clinical Gastroenterology and Hepatology, 2020, 18, 954-962.e6.	4.4	5
134	Beyond obesity: Is cholesterolâ€induced liver injury the cause of nonâ€alcoholic steatohepatitis?. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1412-1414.	2.8	4
135	Reply to: "Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything―and "More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations― Journal of Hepatology, 2018, 68, 219-220.	3.7	4
136	Sex difference in liver-related mortality and transplantation associated with dietary cholesterol in chronic hepatitis C virus infection. British Journal of Nutrition, 2016, 115, 193-201.	2.3	3
137	Obesity and diabetes accelerate hepatocarcinogenesis via hepatocyte proliferation independent of NF-κB or Akt/mTORC1. Journal of Clinical and Translational Research, 2016, 2, 26-37.	0.3	3
138	How can we improve prioritization for liver transplantation in patients with hepatocellular carcinoma?. Liver Transplantation, 2016, 22, 1321-1323.	2.4	2
139	Bilirubin and colorectal cancer: authors' reply. Alimentary Pharmacology and Therapeutics, 2006, 24, 1504-1504.	3.7	1
140	Reply. Hepatology, 2017, 65, 2125-2126.	7.3	1
141	Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication. Hepatology Communications, 2021, 5, 1465-1468.	4.3	1
142	Adapted time-varying covariates Cox model for predicting future cirrhosis development performs well in a large hepatitis C cohort. BMC Medical Informatics and Decision Making, 2021, 21, 347.	3.0	1
143	Serum bilirubin and risk of colorectal cancer: authors' reply. Alimentary Pharmacology and Therapeutics, 2006, 24, 1259-1261.	3.7	0
144	Reply: Towards a better liver transplant allocation system. Liver Transplantation, 2007, 13, 937-937.	2.4	0

#	Article	IF	CITATIONS
145	Reply. Gastroenterology, 2016, 150, 535-537.	1.3	0
146	Editorial: hepatocellular carcinoma in the absence of cirrhosis—a nightmare without solution. Alimentary Pharmacology and Therapeutics, 2019, 50, 1062-1063.	3.7	0
147	Editorial: benefits of <scp>HCV</scp> eradication beyond the liver. Alimentary Pharmacology and Therapeutics, 2019, 49, 1364-1365.	3.7	0
148	Reply. Gastroenterology, 2019, 156, 1218-1220.	1.3	0
149	Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment― Journal of Hepatology, 2019, 70, 211-212.	3.7	0
150	Reply. Clinical Gastroenterology and Hepatology, 2020, 19, 1992-1993.	4.4	0
151	Editorial: is there a â€~precursor' HCC lesion and can it be detected by hepatobiliary contrastâ€enhanced magnetic resonance imaging?. Alimentary Pharmacology and Therapeutics, 2021, 54, 202-203.	3.7	0